Sebastian Schätzle (Enzymicals AG)

Schätzle, Sebastian (Enzymicals 202203– CBO before Alchemab Therapeutics)

	Organisation	Enzymicals AG
	Former/major organisation	Alchemab Therapeutics Ltd.
	Product	industrial biotechnology
	Product 2	industrial enzyme

Enzymicals AG. (3/8/22). "Press Release: Enzymicals AG Board of Supervisors Appoints New Management with Dr. Erik de Vries as CEO". Greifswald.

Today, the Supervisory Board of Enzymicals AG, consisting of Chairman Prof. Dr. Uwe Bornscheuer (Greifswald University), Dr. Martin Langer (BRAIN Biotech AG, ticker BNN.DE) and Prof. Dr. Dagmar Braun (Braun Beteiligungs GmbH), appointed Dr. Erik de Vries as the new CEO of Enzymicals AG. Alongside Dr. de Vries, Dr. Sebastian Schätzle is appointed as Chief Business Officer and Dr. David Liese as Chief Operating Officer. This team will ensure the long-term development of the company.

This management change was set in motion due to the health situation of the outgoing CEO Dr. Ulf Menyes’ at the end of last year. “I noticed that, due to my health, I could not lead Enzymicals with the commitment and energy anymore that I wished to. Fortunately, the Advisory Board and Dr. de Vries have agreed that I can help in the transition of my duties and responsibilities over to him and the team in the next few months, after which I will stay involved to assist Enzymicals as an advisor and coordinator of specific projects on a part-time basis,” said Dr. Menyes.

With the advances in biotechnology over the past several years, Enzymicals is excellently positioned in the market as a developer of chemo-enzymatic processes and technologies for pharma, food and beverage, fine chemicals and chemical industry – for instance technologies for enzymatic polymer degradations – from gram to ton scale.

Prof. Uwe Bornscheuer, Chairman of the Board of Enzymicals AG, stated: “On behalf of everybody at and around Enzymicals, I wish to express my deep gratitude to Dr. Ulf Menyes for his more than ten years of dedication to the company. He has well positioned Enzymicals in the market and we are looking forward to his valuable contributions as an advisor. With the newly formed management team around Dr. Erik de Vries, we expect further growth of the business of Enzymicals. We are looking forward to the years to come and fully support the team.“

“Enzymicals is positioned for a bright future. There is a lot of untapped potential in the market with the advent of the Bio-Economy and global sustainability goals. It is exciting to be leading Enzymicals AG and to work together with my management team and our group of expert employees,” added Dr. de Vries as the new CEO.

About Dr. Erik de Vries

Erik de Vries has studied Organic Chemistry at the University of Groningen in The Netherlands. After obtaining his PhD at the same university in 1997 and during 8 years of postdoc, he started his own spin-off company involved in enzymatic technology. After a successful sale of the company to Codexis, Inc, he moved to California to work at Codexis in various functions with increasing responsibility. After Codexis, Erik was Technical Sales Manager for the Americas for the LifeTech™ line of resins at Purolite, Regional Sales Manager North America at the strain engineering company Amyris and then West Coast Business Development Manager at the Swiss pharma contract manufacturer Dottikon Exclusive Synthesis AG. After moving back to his home base in The Netherlands, Erik started his own biotechnology consulting company and has been involved worldwide in the early stages of numerous biotech and deep tech start-up initiatives. Erik currently is a member of the (Technical) Advisory Boards of FabricNano Ltd (London, UK) and of Allozymes Pte Ltd (Singapore). Erik brings a large network of connections in the biotech, renewable chemicals, cosmetic ingredients and pharmaceuticals areas into Enzymicals AG.

About Dr. Sebastian Schätzle

Sebastian Schätzle studied Biochemistry and obtained his PhD in 2012 at the University of Greifswald. Afterwards, he gained many years of experience in international research groups as postdoc and Senior Scientist at the University of Texas at Austin and ETH Zürich, respectively. In 2020, he joined Alchemab Therapeutics as Senior Scientist and gained valuable insights into the biotech startup scene, before returning to his adopted home Greifswald to take the role as CBO at Enzymicals AG.

About Dr. David Liese

David Liese finished the training as lab assistant at Evonik Industries AG in Essen in 2011. He then studied Chemistry at the University of Duisburg-Essen and obtained his PhD in 2020 at the same university supported with a scholarship of Evonik Industries AG. Since 2020 David is an employee of Enzymicals AG. Here he is responsible for the project management and coordination of the EU-funded project MACBETH (Membranes And Catalysts Beyond Economic and Technological Hurdles).

For more information
www.enzymicals.com

info@enzymicals.com